Advertisement

Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling

  • Yigang Qian
  • Junfang Deng
  • Haiyang Xie
  • Lei Geng
  • Lin Zhou
  • Yan Wang
  • Shenyong Yin
  • Xiaowen Feng
  • Shusen ZhengEmail author
Original Paper

Abstract

Purpose

Toll-like receptor 4 (TLR4) was found to be aberrantly expressed in bladder cancer, inducing some genes expression and facilitating tumor progression. Recent data suggest that tumor associated Interleukin-6 (IL-6) correlates with tumor size and grade in bladder cancer. However, the molecule mechanisms of the induction of IL-6 response in bladder cancer cells are not well elucidated. In this study, we manage to find out whether TLR4 signaling is involved in the production of IL-6 by human bladder cancer cells, and the detailed molecule mechanisms by which IL-6 is up-regulated.

Methods

We selected human bladder cancer T24 cell line in the present study, and examined its expression of TLR4 and CD14 by using flow cytometry. TLR4 signaling was activated by lipopolysaccharide (LPS) and IL-6 secretion in culture supernatants was tested by using ELISA kit. The expression of p38, ERK, JNK and Akt were determined by western-blot analysis using specific antibodies.

Results

Our study demonstrated that CD14 and TLR4 were constitutively expressed in T24 cells and activation of TLR4 signaling by LPS resulted in phosphorylation of MAPK and PI3K pathways and up-regulation of IL-6 in dose- and time-dependent manner. Pretreatment of cells with SB203580 (inhibitor of p38) and PD98059 (inhibitor of ERK) attenuated LPS-induced IL-6 expression, whereas LY294002 (inhibitor of PI3K) markedly amplified the LPS-stimulated synthesis of IL-6.

Conclusions

Our results demonstrate that activation of TLR4 signaling in bladder cancer cells induces tumor-associated IL-6 expression via activation of p38 and ERK, whereas activation of PI3K/Akt exerts an opposing action.

Keywords

TLR4 IL-6 Bladder cancer MAPK PI3K 

Notes

Acknowledgments

Project supported by the National Basic Research Program 973 from Ministry of Science and Technology in China (No. 2003CB515501) and Science and Technology Department of Zhejiang Province (No. 2006C33027).

Conflict of interest statement

On behalf of all authors, I certify that there is no actual or potential conflict of interest in relation to this article entitled ‘Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling’ for consideration to publish in the Journal of Cancer Research and Clinical Oncology.

References

  1. Aksoy E, Vanden Berghe W, Detienne S, Amraoui Z, Fitzgerald KA, Haegeman G et al (2005) Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-kappa B activation and IFN-beta synthesis downstream of Toll-like receptor 3 and 4. Eur J Immunol 5(7):2200–2209. doi: 10.1002/eji.200425801 CrossRefGoogle Scholar
  2. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR et al (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257–1266PubMedGoogle Scholar
  3. Cardillo MR, Sale P, Di Silverio F (2000) Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 20(6B):4579–4583PubMedGoogle Scholar
  4. Dong H, Zhu G, Tamada K, Chen L (1999) B7–H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5(12):1365–1369. doi: 10.1038/70932 PubMedCrossRefGoogle Scholar
  5. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al (2002) Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800PubMedGoogle Scholar
  6. El-Salahy EM (2002) Evaluation of cytokeratin-19 & cytokeratin-20 and interleukin-6 in Egyptian bladder cancer patients. Clin Biochem 35(8):607–613. doi: 10.1016/S0009-9120(02)00382-X PubMedCrossRefGoogle Scholar
  7. Feng GJ, Goodridge HS, Harnett MM, Wei XQ, Nikolaev AV, Higson AP et al (1999) Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunol 163(12):6403–6412PubMedGoogle Scholar
  8. Fukao T, Koyasu S (2003) PI3K and negative regulation of TLR signaling. Trends Immunol 24(7):358–363. doi: 10.1016/S1471-4906(03)00139-X PubMedCrossRefGoogle Scholar
  9. Gabay C (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther 8(Suppl 2):S3. doi: 10.1186/ar1917 PubMedCrossRefGoogle Scholar
  10. Guha M, Mackman N (2002) The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 277(35):32124–32132. doi: 10.1074/jbc.M203298200 PubMedCrossRefGoogle Scholar
  11. Horwood NJ, Page TH, McDaid JP, Palmer CD, Campbell J, Mahon T et al (2006) Bruton’s tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 176(6):3635–3641PubMedGoogle Scholar
  12. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH et al (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65(12):5009–5014. doi: 10.1158/0008-5472.CAN-05-0784 PubMedCrossRefGoogle Scholar
  13. Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19(3):573–580PubMedGoogle Scholar
  14. Okamoto M, Hattori K, Oyasu R (1997) Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 72(1):149–154. doi:10.1002/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-DPubMedCrossRefGoogle Scholar
  15. Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C (2002) European association of urology (EAU) working group on oncological urology. Guidelines on bladder cancer. Eur Urol 41(2):105–112. doi: 10.1016/S0302-2838(01)00026-4 PubMedCrossRefGoogle Scholar
  16. Otto G, Braconier J, Andreasson A, Svanborg C (1999) Interleukin-6 and disease severity in patients with bacteremic and nonbacteremic febrile urinary tract infection. J Infect Dis 179(1):172–179. doi: 10.1086/314534 PubMedCrossRefGoogle Scholar
  17. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP (1990) Biology and management of bladder cancer. N Engl J Med 322(16):1129–1138PubMedGoogle Scholar
  18. Scherle PA, Jones EA, Favata MF, Daulerio AJ, Covington MB, Nurnberg SA et al (1998) Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J Immunol 161(10):5681–5686PubMedGoogle Scholar
  19. Seguchi T, Yokokawa K, Sugao H, Nakano E, Sonoda T, Okuyama A (1992) Interleukin-6 activity in urine and serum in patients with bladder carcinoma. J Urol 148(3):791–794PubMedGoogle Scholar
  20. Shan X, Hu A, Veler H, Fatma S, Grunstein JS, Chuang S et al (2006) Regulation of Toll-like receptor 4-induced proasthmatic changes in airway smooth muscle function by opposing actions of ERK1/2 and p38 MAPK signaling. Am J Physiol Lung Cell Mol Physiol 291(3):L324–L333. doi: 10.1152/ajplung.00056.2006 PubMedCrossRefGoogle Scholar
  21. Shimizu T, Yokota S, Takahashi S, Kunishima Y, Takeyama K, Masumori N et al (2004) Membrane-anchored CD14 is important for induction of interleukin-8 by lipopolysaccharide and peptidoglycan in uroepithelial cells. Clin Diagn Lab Immunol 11(5):969–976. doi: 10.1128/CDLI.11.5.969-976.2004 PubMedCrossRefGoogle Scholar
  22. Song J, Duncan MJ, Li G, Chan C, Grady R, Stapleton A et al (2007) A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells. PLoS Pathog 3(4):e60. doi: 10.1371/journal.ppat.0030060 PubMedCrossRefGoogle Scholar
  23. Sun R, Tian Z, Kulkarni S, Gao B (2004) IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4 + T cell- and STAT3-dependent manners. J Immunol 172(9):5648–5655PubMedGoogle Scholar
  24. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J et al (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155(4):1233–1238. doi: 10.1016/S0022-5347(01)66226-8 PubMedCrossRefGoogle Scholar
  25. Vabulas RM, Wagner H, Schild H (2002) Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol 270:169–184PubMedGoogle Scholar
  26. Valledor AF, Comalada M, Xaus J, Celada A (2000) The differential time-course of extracellular-regulated kinase activity correlates with the macrophage response toward proliferation or activation. J Biol Chem 275(10):7403–7409. doi: 10.1074/jbc.275.10.7403 PubMedCrossRefGoogle Scholar
  27. Verstrepen L, Bekaert T, Chau TL, Tavernier J, Chariot A, Beyaert R (2008) TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme. Cell Mol Life Sci [Epub ahead of print]Google Scholar
  28. Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martínez-Maza O, Gage JR (2004) Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol 93(8):1007–1011. doi: 10.1016/j.amjcard.2003.12.054 PubMedCrossRefGoogle Scholar
  29. Wang YD, De Vos J, Jourdan M, Couderc G, Lu ZY, Rossi JF et al (2002) Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 21(16):2584–2592. doi: 10.1038/sj.onc.1205355 PubMedCrossRefGoogle Scholar
  30. Yokoyama T, Komori A, Nakamura M, Takii Y, Kamihira T, Shimoda S et al (2006) Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int 26(4):467–476. doi: 10.1111/j.1478-3231.2006.01254.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Yigang Qian
    • 1
  • Junfang Deng
    • 1
  • Haiyang Xie
    • 1
  • Lei Geng
    • 1
  • Lin Zhou
    • 1
  • Yan Wang
    • 1
  • Shenyong Yin
    • 1
  • Xiaowen Feng
    • 1
  • Shusen Zheng
    • 1
    Email author
  1. 1.Department of Hepatobiliary Pancreatic Surgery, Key Lab of Organ Transplantation of Zhejiang Province, Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health. The First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations